Sami Kınıklı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sami Kınıklı has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Esra Kaya Kiliç
Sağlık Bilimleri Üniversitesi, Ankara Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara
3 shared publications - Şerife Altun Demircan
Sağlık Bilimleri Üniversitesi Ankara Eğitim ve Araştırma Hastanesi
3 shared publications - Gülşah Geli̇şİgÜzel
ANKARA EĞİTİM VE ARAŞTIRMA HASTANESİ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ
2 shared publications - Murat Aysin
Balikesir University Faculty of Medicine, Department of Public Health, Balikesir, Turkey
2 shared publications - Serap Yağcı
Medical Microbiology Clinic, Ankara Training and Research Hospital, Ankara 06230, Türkiye
2 shared publications - Gözde Orman
Department of Ophthalmology, University of Health Sciences Ankara Training and Research Hospital, Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
Ocular Syphilis in the Era of Resurgence: Clinical Characteristics and Diagnostic Challenges in a Single-Center Cohort
Background and Objectives: The global resurgence of syphilis has been accompanied by an increasing number of ocular syphilis cases. Ocular syphilis can occur at any stage of infection and has diverse clinical manifestations, making diagnosis challenging. Materials and Methods: We retrospectively reviewed 21 adults diagnosed with ocular syphilis at a tertiary referral center between 2018 and 2023. Diagnosis was based on compatible ophthalmologic findings, together with positive treponemal serology. Demographic, clinical, ophthalmologic, laboratory, cerebrospinal fluid (CSF), imaging, and treatment data were analyzed. Results: A total of 21 patients (30 eyes) were included. The majority were male (87%), with a median age of 44 years, and bilateral involvement occurred in 43% of patients. Blurred vision and decreased visual acuity were the most common presenting symptoms (80%). Uveitis (68.4%), predominantly posterior, and optic neuritis (42.1%) were the most frequent ophthalmologic findings. Serum VDRL was negative in 5 of 21 patients despite positive treponemal serology. Among the 14 patients who underwent lumbar puncture, half had normal cerebrospinal fluid findings. All patients received neurosyphilis-directed antimicrobial therapy. The mean baseline BCVA was 0.38 ± 0.30 logMAR (range, 0–1), improving to 0.16 ± 0.28 logMAR (range, 0–1) at the final follow-up. The improvement in BCVA following treatment was statistically significant (p < 0.001). No eye showed deterioration in BCVA after treatment; visual acuity either improved or remained stable in all eyes. Additionally, all cases of uveitis and optic neuropathy achieved clinical remission during follow-up. Conclusions: Ocular syphilis remains a diagnostic challenge because of its heterogeneous clinical manifestations and the occurrence of negative serum VDRL results or normal cerebrospinal fluid findings in patients who underwent lumbar puncture. These findings highlight the limitations of relying solely on non-treponemal serology or cerebrospinal fluid analysis when evaluating patients with suspected ocular syphilis.
Open AccessOcular Syphilis in the Era of Resurgence: Clinical Characteristics and Diagnostic Challenges in a Single-Center Cohort
Background and Objectives: The global resurgence of syphilis has been accompanied by an increasing number of ocular syphilis cases. Ocular syphilis can occur at any stage of infection and has diverse clinical manifestations, making diagnosis challenging. Materials and Methods: We retrospectively reviewed 21 adults diagnosed with ocular syphilis at a tertiary referral center between 2018 and 2023. Diagnosis was based on compatible ophthalmologic findings, together with positive treponemal serology. Demographic, clinical, ophthalmologic, laboratory, cerebrospinal fluid (CSF), imaging, and treatment data were analyzed. Results: A total of 21 patients (30 eyes) were included. The majority were male (87%), with a median age of 44 years, and bilateral involvement occurred in 43% of patients. Blurred vision and decreased visual acuity were the most common presenting symptoms (80%). Uveitis (68.4%), predominantly posterior, and optic neuritis (42.1%) were the most frequent ophthalmologic findings. Serum VDRL was negative in 5 of 21 patients despite positive treponemal serology. Among the 14 patients who underwent lumbar puncture, half had normal cerebrospinal fluid findings. All patients received neurosyphilis-directed antimicrobial therapy. The mean baseline BCVA was 0.38 ± 0.30 logMAR (range, 0–1), improving to 0.16 ± 0.28 logMAR (range, 0–1) at the final follow-up. The improvement in BCVA following treatment was statistically significant (p < 0.001). No eye showed deterioration in BCVA after treatment; visual acuity either improved or remained stable in all eyes. Additionally, all cases of uveitis and optic neuropathy achieved clinical remission during follow-up. Conclusions: Ocular syphilis remains a diagnostic challenge because of its heterogeneous clinical manifestations and the occurrence of negative serum VDRL results or normal cerebrospinal fluid findings in patients who underwent lumbar puncture. These findings highlight the limitations of relying solely on non-treponemal serology or cerebrospinal fluid analysis when evaluating patients with suspected ocular syphilis.
- Open Access
- 20 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 229
Prospective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Onset Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)-producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aims to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between 1 October 2022 and 29 February 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, hospitalization more than one month prior, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility profiles and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p < 0.05 considered statistically significant. Results: Escherichia coli (n = 142) and Klebsiella spp. (n = 43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). In the multivariate logistic regression analysis, male sex (p = 0.038) and hospitalization more than one month prior (p = 0.016) were identified as independent risk factors for ESBL positivity, while prior antibiotic use in the last three months showed a borderline association (p = 0.055) and did not reach statistical significance. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p < 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 20 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 229
Open AccessProspective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Onset Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)-producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aims to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between 1 October 2022 and 29 February 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, hospitalization more than one month prior, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility profiles and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p < 0.05 considered statistically significant. Results: Escherichia coli (n = 142) and Klebsiella spp. (n = 43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). In the multivariate logistic regression analysis, male sex (p = 0.038) and hospitalization more than one month prior (p = 0.016) were identified as independent risk factors for ESBL positivity, while prior antibiotic use in the last three months showed a borderline association (p = 0.055) and did not reach statistical significance. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p < 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- Open Access
- 15 January 2026
- Published by MDPI AG in Preprints.org
Prospective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Acquired Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)–producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aimed to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between October 1, 2022, and February 29, 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, recent hospitalization, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility pro-files and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p< 0.05 considered statistically significant. Results: Escherichia coli (n=142) and Klebsiella spp. (n=43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). Male sex (p=0.007), history of urinary intervention (p=0.019), hospitalization within the previous month (p< 0.001), and antibiotic use in the last three months (p=0.002) were identified as significant risk factors for ESBL positivity. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p< 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 15 January 2026
- Published by MDPI AG in Preprints.org
Open AccessProspective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Acquired Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)–producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aimed to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between October 1, 2022, and February 29, 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, recent hospitalization, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility pro-files and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p< 0.05 considered statistically significant. Results: Escherichia coli (n=142) and Klebsiella spp. (n=43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). Male sex (p=0.007), history of urinary intervention (p=0.019), hospitalization within the previous month (p< 0.001), and antibiotic use in the last three months (p=0.002) were identified as significant risk factors for ESBL positivity. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p< 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.